Prolactinomas in adolescents: Persistent bone loss after 2 years of prolactin normalization

Clinical Endocrinology

Volumn 52, Issue 3, 2000, Pages 319-327

  Colao, Annamaria ^a,b   Di Somma, Carolina ^a   Loche, Sandro ^c   Di Sarno, Antonella ^a   Klain, Michele ^b   Pivonello, Rosario ^a   Pietrosante, Marco ^a   Salvatore, Marco ^b   Lombardi, Gaetano ^a  

^a Dept of Molec/Clin Endocrinol/O ^*  (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c Ospedale per le Microcitemie   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; COLLAGEN TYPE 1; DOPAMINE RECEPTOR STIMULATING AGENT; OSTEOCALCIN; PROLACTIN; QUINAGOLIDE;

ADOLESCENT; ADULT; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; MALE; ONSET AGE; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AMINOQUINOLINES; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; BROMOCRIPTINE; CASE-CONTROL STUDIES; COLLAGEN; COLLAGEN TYPE I; DOPAMINE AGONISTS; ERGOLINES; FEMALE; FEMUR NECK; HUMANS; LONGITUDINAL STUDIES; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS; PEPTIDES; PITUITARY NEOPLASMS; PROLACTINOMA; REGRESSION ANALYSIS;

EID: 0034073803     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2000.00902.x     Document Type: Article

References (41)

1. Aimaretli, G., Cornell, G., Razzore, P., Bellone, S., Baffoni, C., Arvat, E., Camanni, F. & Ghigo, E. (1998) Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults. Journal of Clinical Endocrinology and Metabolism, 83, 1615-1618.
2. Artese, R., D'Osvaldo, D.H., Molocznik, I., Benencia, H., Oviedo, J., Burman, J.A. & Basso, A. (1998) Pituitary tumors in adolescent patients. Neurological Research, 20, 415-417.
3. Biller, B.M.K., Baum, H.B.A., Rosenthal, D.I., Saxe, V.C., Charpie, P.M. & Klibanski, A. (1992) Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. Journal of Clinical Endocrinology and Metabolism, 75, 692-697.
4. Bonnet, H.G., Dahlen, H.G., Wuttke, W. & Schneider, H.P.G. (1976) Hyperprolactinemic anovulatory syndrome. Journal of Clinical Endocrinology and Metabolism, 42, 132-143.
5. Bonjour, J.P., Theintz, G., Buchs, B., Sloman, D. & Rizzoli, R. (1991) Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. Journal of Clinical Endocrinology and Metabolism, 73, 555-563.
6. Brue, T., Pellegrini, I., Gunz, G., Morange, I., Dewailly, D., Brownell, J., Enjalbert, A. & Jaquet, P. (1992) Effects of dopamine agonists CV 205-502 in human prolactinomas resistant to bromocriptine. Journal of Clinical Endocrinology and Metabolism, 74, 577-584.
7. Cann, C.E., Martin, M.C., Genant, H.K. & Jaffe, R.B. (1984) Decreased spinal mineral content in amenorrheic women. Journal of American Medical Association, 251, 626-630.
8. Carrol, P.V. & Christ, E.R. (1998) Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Journal of Clinical Endocrinology and Metabolism, 83, 382-395.
9. Colao, A., Di Sarno, A., Landi, M.L., Cirillo, S., Sarnacchiaro, F., Facciolli, G., Pivonello, R., Cataldi, M., Merola, B., Annunziato, L. & Lombardi, G. (1997) Long-term and low dose treatment with cabergoline induces macroprolactinoma shrinkage. Journal of Clinical Endocrinology and Metabolism, 82, 3574-3579.
10. Colao, A. & Lombardi, G. (1998) GH and PRL excess. Lancet, 352, 1455-1461.
11. Colao, A., Annunziato, L. & Lombardi, G. (1998a) Treatment of prolactinomas. Annals of Medicine, 30, 452-459.
12. Colao, A., Loche, S., Cappa, M., Di Sarno, A., Landi, M.L., Sarnacchiaro, F., Facciolli, G. & Lombardi, G. (1998b) Prolactinomas in children and adolescents. Clinical presentation and long term follow-up. Journal of Clinical Endocrinology and Metabolism, 83, 2777-2780.
13. Colao, A., Di Somma, C., Pivonello, R., Loche, S., Aimaretti, G., Cerbone, G., Faggiano, A., Corneli, G., Ghigo, E. & Lombardi, G. (1999) Bone loss is correlated to the severity of growth hormone (GH) deficiency in adult patients with hypopituitarism. Journal of Clinical Endocrinology and Metabolism, 84, 1919-1924.
14. De Boer, H., Block, G.-J. & Van Der Veen, E.A. (1995) Clinical aspects of growth hormone deficiency in adults. Endocrine Review, 16, 63-86.
15. Di Somma, C., Colao, A., Di Sarno, A., Klain, M., Landi, M.L., Facciolli, G., Pivonello, R., Panza, N., Salvatore, M. & Lombardi, G. (1998) Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. Journal of Clinical Endocrinology and Metabolism, 83, 807-813.
16. Eriksen, E.F. & Langdahl, B.L. (1997) The pathogenesis of osteoporosis. Hormone Research, 48 (Suppl. 5), 78-82.
17. Glastre, C., Braillou, P., David, L., Cochat, P., Meunier, P.J. & Delmas, P.D. (1990) Measurement of bone mineral content of the lumbar spine by dual x-ray absorptiometry in normal children: correlations with growth parameters. Journal of Clinical Endocrinology and Metabolism, 79, 1330-1333.
18. Greenspan, S.L., Neer, R.M., Ridgway, E.C. & Klibanski, A. (1986) Osteoporosis in men with hyperprolactinemic hypogonadism. Annals of Internal Medicine, 104, 77-82.
19. Greenspan, S.L., Oppenheim, D.S. & Klibanski, A. (1989) Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Annals of Internal Medicine, 110, 526-531.
20. Jackson, J.A., Kleerekoper, M. & Parfitt, M. (1986) Symptomatic osteoporosis in a man with hyperprolactinemic hypogonadism. Annals of Internal Medicine, 105, 543-545.
21. Hoffman, D.M., O'Sullivan, A.J., Baxter, R.C. & Ho, K.Y. (1994) Diagnosis of growth hormone deficiency in adults. Lancet, 343, 1064-1068.
22. Holmes, S.J., Economou, G., Whitehouse, R.W., Adams, J.E. & Shalet, S.M. (1994) Reduced bone mineral density in patients with adult onset growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism, 78, 669-674.
23. Howlett, T.A., Wass, J.A., Grossman, A., Plowman, P.N., Charlesworth, M., Touzel, R., Rees, L.H., Savage, M.O. & Besser, G.M. (1989) Prolactinomas presenting as primary amenorrhoea and delayed or arrested puberty: response to medical therapy. Clinical Endocrinology, 30, 131-140.
24. Hui, S.L., Slemenda, C.W. & Johnston Jr, C.C. (1989) Baseline measurement of bone mass predicts fracture in white women. Annals of Internal Medicine, 111, 353-361.
25. Klibanski, A., Neer, R.M., Beitins, I.Z., Ridgway, C., Zarvas, N.T. & McArthur, J.W. (1980) Decreased bone density in amenorrheic women. New England Journal of Medicine, 303, 1511-1514.
26. Matkovic, V., Fontana, D., Tominac, C., Goel, P. & Chesnut, C.H. (1990) Factors which influence peak bone mass formation: a steady calcium balance and the inheritance of bone mass in adolescent females. American Journal of Clinical Nutrition, 52, 878-888.
27. Matkovic, V. (1996) Skeletal development and bone turnover revisited. Journal of Clinical Endocrinology and Metabolism, 81, 2013-2016.
28. Melton, L.J.I.I.I., Atkinson, E.J., O'Fallon, W.M., Wahner, H.W. & Riggs, B.L. (1993) Long-term fracture prediction by bone mineral assessed at different skeletal sites. Journal of Bone Mineral Research, 8, 1227-1234.
29. Oberfield, S.E., Nino, M., Riddick, L., Pang, S., Nagel, M., Khandji, A., Kairam, R. & Levine, L.S. (1992) Combined bromocriptine and growth hormone (GH) treatment in GH-deficient children with macroprolactinoma in situ. Journal of Clinical Endocrinology and Metabolism, 75, 87-90.
30. Park, S.K., Keenan, M.W. & Selmanoff, M. (1993) Graded hyperprolactinemia first suppresses LH pulse frequency and then pulse amplitude in castrated male rats. Neuroendocrinology, 58, 448-453.
31. Pocock, N.A., Eisman, J.A., Hopper, J.L., Yeates, M.G., Sambrook, P.N. & Eberi, S. (1987) Genetic determinants of bone mass in adults: a twin study. Journal of Clinical Investigation, 80, 406-710.
32. Schlecthe, J.A., Sherman, B. & Martin, R. (1983) Bone density in amenorrheic women with and without hyperprolactinemia. Journal of Clinical Endocrinology and Metabolism, 56, 1120-1123.
33. Schlechte, J., El-Khoury, G., Kathol, M. & Walkner, L. (1987) Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. Journal of Clinical Endocrinology and Metabolism, 64, 1021-1026.
34. Seeman, E., Melton, L.J.I.I., O'Fallon, W.M. & Riggs, B.L. (1983) Risk factors for spinal osteoporosis in men. American Journal of Medicine, 75, 977-983.
35. Shalet, S.M., Toogood, A. Rahim, A. & Brennan, B.M.D. (1998) The diagnosis of growth hormone deficiency in children and adults. Endocrine Review, 19, 203-223.
36. Tyson, D., Reggiardo, D., Sklar, C. & David, R. (1993) Prolactinsecreting macroadenomas in adolescents. Response to bromocriptine therapy. American Journal of Disease Children, 147, 1057-1061.
37. Theinlz, G., Buchs, B., Rizzoli, R., Slosman, D., Clavien, H., Sizonenko, P.C. & Bonjour, J.P. (1992) Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. Journal of Clinical Endocrinology and Metabolism, 75, 1060-1065.
38. Van der Lely, A.J., Brownell, J. & Lamberts, S.W.J. (1991) The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine. Journal of Clinical Endocrinology and Metabolism, 72, 1136-1141.
39. Wardlaw, S.L. & Bilezikian, J.P. (1992) Hyperprolactinemia and osteopenia. Journal of Clinical Endocrinology and Metabolism, 75, 690-691.
40. Wasnich,R.D., Ross, P.D., Heilbrun, L.K. & Vogel, J.M. (1985) Prediction of postmenopausal fracture risk with use of bone mineral measurements. American Journal of Obstetric and Gynecology, 153, 745-751.
41. Webster, J., Piscitelli, G., Polli, A., Ferrari, C.I., Ismail, I. & Scanlon, M.F. (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. New England Journal of Medicine, 331, 904-909.